Their unique capacity to simultaneously enhance GLP-1 signaling and potential to reinforce the TXNIP–thioredoxin antioxidant defense system makes them strong, holistic candidates for further development in the management of MetS. The gene discussed is GLP1R; the disease is metabolic syndrome.